FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912019524> ?p ?o ?g. }

• W2912019524 endingPage "e0007173" @default.
• W2912019524 startingPage "e0007173" @default.
• W2912019524 abstract "Background Miltefosine (MF) is the only oral drug available for treatment of visceral leishmaniasis (VL) and post-kala-azar dermal leishmaniasis (PKDL). Although the drug is effective and well tolerated in treatment of VL, the efficacy and safety of MF for longer treatment durations (>28 days) in PKDL remains unclear. This study provides an overview of the current knowledge about safety and efficacy of long treatment courses with MF in PKDL, as a strategy in the VL elimination in South Asia. Methodology/Principal findings Literature was searched systematically for articles investigating MF treatment in PKDL. A meta-analysis included eight studies (total 324 PKDL patients) to estimate the efficacy of MF in longer treatment regimens (range 6–16 weeks). We found a per-protocol (PP) initial cure rate of 95.2% (95%CI 89.6–100.8) and a PP definite cure rate of 90% (95%CI 81.6–96.3). Descriptive analysis showed that 20% of patients experienced adverse events, which mostly had an onset in the first week of treatment and were likely to get more severe after four weeks of treatment. Gastrointestinal (GI) side effects such as vomiting, nausea, diarrhoea, and abdominal pain were most common. Conclusions/Significance Longer treatment regimens with MF are effective in PKDL patients in India, however with the caveat that the efficacy has recently been observed to decline. GI side effects are frequent, although mostly mild or moderate. However, on the basis of limited data, we cannot conclude that longer MF treatment regimens are safe. Moreover, VL and PKDL pharmacovigilance studies indicate a risk for serious adverse events, questioning the safety of MF. The provision of safer treatment regimens for PKDL patients are therefore recommended. Until these regimens are identified, it should be considered to halt the use of MF monotherapy for PKDL in order to preserve the drug’s efficacy." @default.
• W2912019524 created "2019-02-21" @default.
• W2912019524 creator A5031626110 @default.
• W2912019524 creator A5055514458 @default.
• W2912019524 creator A5063984878 @default.
• W2912019524 creator A5088892098 @default.
• W2912019524 date "2019-02-11" @default.
• W2912019524 modified "2023-10-16" @default.
• W2912019524 title "The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia – A review and meta-analysis" @default.
• W2912019524 cites W1825050981 @default.
• W2912019524 cites W1957126776 @default.
• W2912019524 cites W1966542035 @default.
• W2912019524 cites W1978605483 @default.
• W2912019524 cites W1991674117 @default.
• W2912019524 cites W2003369163 @default.
• W2912019524 cites W2013510637 @default.
• W2912019524 cites W2027115732 @default.
• W2912019524 cites W2032761636 @default.
• W2912019524 cites W2056282461 @default.
• W2912019524 cites W2063982195 @default.
• W2912019524 cites W2081731516 @default.
• W2912019524 cites W2082066472 @default.
• W2912019524 cites W2090327420 @default.
• W2912019524 cites W2101502132 @default.
• W2912019524 cites W2126420606 @default.
• W2912019524 cites W2131358046 @default.
• W2912019524 cites W2133675087 @default.
• W2912019524 cites W2133839431 @default.
• W2912019524 cites W21364562 @default.
• W2912019524 cites W2148707789 @default.
• W2912019524 cites W2158168571 @default.
• W2912019524 cites W2161374186 @default.
• W2912019524 cites W2171230483 @default.
• W2912019524 cites W2432468500 @default.
• W2912019524 cites W2614458392 @default.
• W2912019524 cites W2755591444 @default.
• W2912019524 cites W2770374950 @default.
• W2912019524 cites W2884207253 @default.
• W2912019524 cites W2890157226 @default.
• W2912019524 cites W4231256920 @default.
• W2912019524 doi "https://doi.org/10.1371/journal.pntd.0007173" @default.
• W2912019524 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6386412" @default.
• W2912019524 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30742620" @default.
• W2912019524 hasPublicationYear "2019" @default.
• W2912019524 type Work @default.
• W2912019524 sameAs 2912019524 @default.
• W2912019524 citedByCount "39" @default.
• W2912019524 countsByYear W29120195242019 @default.
• W2912019524 countsByYear W29120195242020 @default.
• W2912019524 countsByYear W29120195242021 @default.
• W2912019524 countsByYear W29120195242022 @default.
• W2912019524 countsByYear W29120195242023 @default.
• W2912019524 crossrefType "journal-article" @default.
• W2912019524 hasAuthorship W2912019524A5031626110 @default.
• W2912019524 hasAuthorship W2912019524A5055514458 @default.
• W2912019524 hasAuthorship W2912019524A5063984878 @default.
• W2912019524 hasAuthorship W2912019524A5088892098 @default.
• W2912019524 hasBestOaLocation W29120195241 @default.
• W2912019524 hasConcept C126322002 @default.
• W2912019524 hasConcept C141071460 @default.
• W2912019524 hasConcept C16005928 @default.
• W2912019524 hasConcept C197934379 @default.
• W2912019524 hasConcept C203014093 @default.
• W2912019524 hasConcept C2776555147 @default.
• W2912019524 hasConcept C2778689377 @default.
• W2912019524 hasConcept C2780580376 @default.
• W2912019524 hasConcept C2780852908 @default.
• W2912019524 hasConcept C2781417161 @default.
• W2912019524 hasConcept C71924100 @default.
• W2912019524 hasConceptScore W2912019524C126322002 @default.
• W2912019524 hasConceptScore W2912019524C141071460 @default.
• W2912019524 hasConceptScore W2912019524C16005928 @default.
• W2912019524 hasConceptScore W2912019524C197934379 @default.
• W2912019524 hasConceptScore W2912019524C203014093 @default.
• W2912019524 hasConceptScore W2912019524C2776555147 @default.
• W2912019524 hasConceptScore W2912019524C2778689377 @default.
• W2912019524 hasConceptScore W2912019524C2780580376 @default.
• W2912019524 hasConceptScore W2912019524C2780852908 @default.
• W2912019524 hasConceptScore W2912019524C2781417161 @default.
• W2912019524 hasConceptScore W2912019524C71924100 @default.
• W2912019524 hasIssue "2" @default.
• W2912019524 hasLocation W29120195241 @default.
• W2912019524 hasLocation W29120195242 @default.
• W2912019524 hasLocation W29120195243 @default.
• W2912019524 hasLocation W29120195244 @default.
• W2912019524 hasLocation W29120195245 @default.
• W2912019524 hasOpenAccess W2912019524 @default.
• W2912019524 hasPrimaryLocation W29120195241 @default.
• W2912019524 hasRelatedWork W1866137602 @default.
• W2912019524 hasRelatedWork W1913340848 @default.
• W2912019524 hasRelatedWork W1975774630 @default.
• W2912019524 hasRelatedWork W2031190272 @default.
• W2912019524 hasRelatedWork W2102989589 @default.
• W2912019524 hasRelatedWork W2139551085 @default.
• W2912019524 hasRelatedWork W2150604586 @default.
• W2912019524 hasRelatedWork W2526654304 @default.
• W2912019524 hasRelatedWork W4225832470 @default.
• W2912019524 hasRelatedWork W4245411047 @default.

• next